Coleman named VP of medical affairs at GenomOncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JOSHUA COLEMAN was named vice president of medical affairs at GenomOncology.

He will oversee clinical content development and curation of scientific evidence, enhancing the company’s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with a seamless workflow for the interpretation of genetic sequencing data and clinical decision support, from quality control through reporting.

Prior to joining GenomOncology, Coleman held an appointment of assistant professor at The Ohio State University College of Medicine and practiced molecular genetic pathology in the James Cancer Hospital Molecular Laboratory. He is board-certified in hematopathology and molecular genetic pathology.

YOU MAY BE INTERESTED IN

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges.  Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login